4.5 Review

Targeting the PI3K pathway for cancer therapy

期刊

FUTURE MEDICINAL CHEMISTRY
卷 4, 期 9, 页码 1153-1169

出版社

FUTURE SCI LTD
DOI: 10.4155/FMC.12.56

关键词

-

资金

  1. ArQule Inc.
  2. Boehringer-Ingelheim Inc.
  3. Genentech Inc.
  4. Peregrine Pharmaceuticals
  5. NIH CTSA [KL2RR024983]
  6. NCI Clinical Investigator Team Leadership Award [1P30 CA142543-01]

向作者/读者索取更多资源

The P13K pathway plays an important role in key cellular functions such as cell growth, proliferation and survival. Genetic and epigenetic alterations in different pathway components lead to aberrant pathway activation and have been observed in high frequencies in various tumor types. Consequently, significant effort has been made to develop antineoplastic agents targeting different nodes in this pathway. Additionally, PI3K pathway status may have predictive and prognostic implications, and may contribute to drug resistance in tumor cells. This article provides an overview of our current knowledge of the PI3K pathway with an emphasis on its application in cancer treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据